Patents Assigned to Galderma S.A.
  • Patent number: 9333172
    Abstract: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: May 10, 2016
    Assignee: GALDERMA S.A.
    Inventors: Nancy Puglia, Jerry Roth, Rosario Ramirez
  • Patent number: 9233117
    Abstract: Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 12, 2016
    Assignee: Galderma S. A.
    Inventors: Jean Jacovella, Jean-Paul Chappuis, Nathalie Sordello Wagner, Michael Graeber, Alexandre Kaoukhov, Laurence Salin, Michel Poncet, Philippe Briantais, Khaled Benkali
  • Patent number: 9233118
    Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 12, 2016
    Assignee: Galderma S.A.
    Inventors: Jean Jacovella, Jean-Paul Chappuis, Alexandre Kaoukhov, Michael Graeber, Michel Poncet, Philippe Briantais, Laurence Salin
  • Patent number: 9125927
    Abstract: Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: September 8, 2015
    Assignee: GALDERMA S.A.
    Inventors: Alexandre Kaoukhov, Colette Pernin
  • Patent number: 9089587
    Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: July 28, 2015
    Assignee: Galderma S.A.
    Inventors: Jean Jacovella, Jean-Paul Chappuis, Nathalie Sordello Wagner
  • Patent number: 8987218
    Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: March 24, 2015
    Assignee: Galderma S.A.
    Inventors: Alexandre Kaoukhov, Christophe Villard, Philippe Bouissou
  • Publication number: 20150045315
    Abstract: A method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by an insect or arthropod sting or bite, or a skin contact with a noxious weed or plant is disclosed. The method includes topically applying a dermatological composition containing an avermectin compound to an affected area immediately after said sting or bite, or said skin contact occurs. The method further includes moistening the affected area first prior to application of the dermatological composition.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 12, 2015
    Applicant: GALDERMA S. A.
    Inventors: Jeffrey D. Parks, L. Dean Parks
  • Publication number: 20150011489
    Abstract: Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 8, 2015
    Applicant: GALDERMA S.A.
    Inventor: Jean JACOVELLA
  • Publication number: 20150011490
    Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 8, 2015
    Applicant: GALDERMA S.A.
    Inventor: Jean JACOVELLA
  • Publication number: 20150011491
    Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.
    Type: Application
    Filed: April 21, 2014
    Publication date: January 8, 2015
    Applicant: GALDERMA S.A.
    Inventor: Jean JACOVELLA
  • Patent number: 8912151
    Abstract: A method of treating hemorrhoids is disclosed. The method includes locally administering a composition including an effective amount of one or more macrocyclic lactone compounds, including avermectin compounds, milbemycin compounds, or mixture thereof and a pharmaceutically acceptable carrier to the affected anorectal region of an individual suffering from hemorrhoid.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: December 16, 2014
    Assignee: Galderma S.A.
    Inventors: L. Dean Parks, Jeffrey D. Parks
  • Patent number: 8901091
    Abstract: A method of treating herpes simplex virus infection or varicella zoster virus infection is disclosed. The method includes topically applying a composition containing an effective amount of one or more macrocyclic lactone compounds, including avermectin compounds or milbemycin compounds and a pharmaceutically acceptable carrier to the affected area of an individual suffering from herpes simplex virus infection or varicella zoster virus infection.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: December 2, 2014
    Assignee: Galderma S.A.
    Inventors: L. Dean Parks, Jeffrey D. Parks
  • Patent number: 8901163
    Abstract: A method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by an insect or arthropod sting or bite, or a skin contact with a noxious weed or plant is disclosed. The method includes topically applying a dermatological composition containing an avermectin compound to an affected area immediately after said sting or bite, or said skin contact occurs. The method further includes moistening the affected area first prior to application of the dermatological composition.
    Type: Grant
    Filed: January 3, 2007
    Date of Patent: December 2, 2014
    Assignee: Galderma S.A.
    Inventors: Jeffrey D. Parks, L. Dean Parks
  • Patent number: 8901090
    Abstract: A method of treating otitis externa is disclosed. The method includes topically applying an otic composition containing an effective amount of one or more macrocyclic lactone compounds, including avermectin compounds or milbemycin compounds and a pharmaceutically acceptable carrier into the external auditory canal and the auricle of an affected ear of an individual suffering from otitis externa.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: December 2, 2014
    Assignee: Galderma S.A.
    Inventors: L. Dean Parks, Jeffrey D. Parks
  • Patent number: 8858967
    Abstract: Pharmaceutical cream-gel compositions useful for the treatment of a variety of dermatological conditions, disorders and afflictions, in particular of rosacea, contain at least one avermectin compound active principle, and which also contain an oily phase dispersed in an aqueous phase by means of a non-surfactant polymeric emulsifier, the oily phase comprising oils having a melting point below 30° C. and being free of solid fats having a melting point above 30° C., formulated into a physiologically acceptable medium therefor.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: October 14, 2014
    Assignee: Galderma S.A.
    Inventors: Fanny Astruc, Sandrine Orsoni, Laurent Fredon
  • Patent number: 8859603
    Abstract: Metronidazole is solubilized in an aqueous phase, by mixing same with niacinamide and at least two glycolic cosolvents; the resulting solutions and pharmaceutical compositions comprised thereof are useful for the treatment of dermatological conditions/afflictions, notably rosacea.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: October 14, 2014
    Assignee: Galderma S.A.
    Inventors: Claire Mallard, Alain Brzokewicz
  • Publication number: 20140271834
    Abstract: The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean Cmax of the pharmaceutical composition is within 80.00% to 125.00% of a Cmax value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC(0-?) of the pharmaceutical composition is within 80.00% to 125.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 18, 2014
    Applicants: Cerovene, Inc., Galderma S.A.
    Inventors: Jean-Pierre Etchegaray, Nathalie Wagner, Manish S. Shah, Ray J. Difalco
  • Publication number: 20140256689
    Abstract: Novel compositions in petroleum jelly-free unguent form, in particular for topical application, contain a vitamin D compound and optionally an active agent of the family of steroidal anti-inflammatory agents.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 11, 2014
    Applicant: GALDERMA S.A.
    Inventors: Nathalie WILLCOX, Nathalie Barthez, Karine Nadau-Fourcade, Claire Mallard
  • Publication number: 20140256662
    Abstract: Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.
    Type: Application
    Filed: May 22, 2014
    Publication date: September 11, 2014
    Applicant: Galderma S.A.
    Inventors: Alexandre KAOUKHOV, Christophe VILLARD, Philippe BOUISSOU
  • Publication number: 20140243297
    Abstract: Novel compositions in petroleum jelly-free unguent form, in particular for topical application, contain a vitamin D compound and optionally an active agent of the family of steroidal anti-inflammatory agents.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 28, 2014
    Applicant: GALDERMA S.A.
    Inventors: Nathalie WILLCOX, Nathalie BARTHEZ, Karine NADAU-FORUCADE, Claire MALLARD